D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile

Nature Communications

Volumn 7, Issue , 2016, Pages

  Valleix, Sophie ^a,b,c,d   Verona, Guglielmo ^e,f   Jourde Chiche, Noémie ^g   Nédelec, Brigitte ^b,c,d   Mangione, P Patrizia ^e,f   Bridoux, Frank ^h   Mangé, Alain ^i,j,k   Dogan, Ahmet ^l,m   Goujon, Jean Michel ^h   Lhomme, Marie ⁿ   Dauteuille, Carolane ^d   Chabert, Michèle ^d,o   Porcari, Riccardo ^e   Waudby, Christopher A ^p   Relini, Annalisa ^q   Talmud, Philippa J ^e   Kovrov, Oleg ^r   Olivecrona, Gunilla ^r   Stoppini, Monica ^f   Christodoulou, John ^p   Hawkins, Philip N ^e   Grateau, Gilles ^s   Delpech, Marc ^a   Kontush, Anatol ^d   Gillmore, Julian D ^e   Kalopissis, Athina D ^d   Bellotti, Vittorio ^e,f   more..

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b IMAGINE INSTITUTE   (France)

^c INSERM   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF PAVIA   (Italy)

^g HÔPITAL DE LA CONCEPTION   (France)

^h UNIVERSITÉ DE POITIERS   (France)

ⁱ INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^j UNIV MONTPELLIER   (France)

^k CENTRE VAL D AURELLE   (France)

^l MAYO CLINIC   (United States)

^m MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁿ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^o PSL RESEARCH UNIVERSITY   (France)

^p UNIVERSITY OF LONDON   (United Kingdom)

^q UNIVERSITY OF GENOA   (Italy)

^r UMEÅ UNIVERSITY   (Sweden)

^s HÔPITAL TENON   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; APOLIPOPROTEIN C3; CREATININE; D25V PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; PROTEIN VARIANT; PROTEOME; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

CARDIOVASCULAR DISEASE; ENZYME ACTIVITY; LIPID; PROTEIN;

ADULT; ARTICLE; ATOMIC FORCE MICROSCOPY; BRONCHUS BIOPSY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; END STAGE RENAL DISEASE; ESOPHAGITIS; FAMILY HISTORY; GASTROESOPHAGEAL REFLUX; HEART AMYLOIDOSIS; HEART PROTECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYDRODYNAMICS; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOGOLD STAINING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY AMYLOIDOSIS; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LASER MICRODISSECTION; LIPOPROTEIN BLOOD LEVEL; MALE; MASS SPECTROMETRY; MIDDLE AGED; NITROGEN NUCLEAR MAGNETIC RESONANCE; PROTEIN SECONDARY STRUCTURE; PROTEIN STRUCTURE; PROTEINURIA; PROTEOMICS; PROTON NUCLEAR MAGNETIC RESONANCE; PRURITUS; RAYNAUD PHENOMENON; SALIVARY GLAND BIOPSY; SJOEGREN SYNDROME; STAPHYLOCOCCUS INFECTION; TRANSMISSION ELECTRON MICROSCOPY; TRIACYLGLYCEROL BLOOD LEVEL; AGED; AMYLOIDOSIS; CARDIOVASCULAR DISEASES; CHEMISTRY; FEMALE; FRANCE; GENETICS; HYPERLIPOPROTEINEMIA; METABOLISM; MISSENSE MUTATION; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PEDIGREE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; APOLIPOPROTEIN C-III; BASE SEQUENCE; CARDIOVASCULAR DISEASES; FEMALE; FRANCE; HUMANS; HYPERLIPOPROTEINEMIAS; LIPOPROTEINS, HDL; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PEDIGREE;

EID: 84955513374     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10353     Document Type: Article

References (56)

1. Havel, R. J., Kane, J. P. & Kashyap, M. L. Interchange of apolipoproteins between chylomicrons and high density lipoproteins during alimentary lipemia in man. J. Clin. Invest. 52, 32-38 (1973).
2. Ooi, E. M., Barrett, P. H., Chan, D. C. & Watts, G. F. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin. Sci. 114, 611-624 (2008).
3. Wang, C. S., McConathy, W. J., Kloer, H. U. & Alaupovic, P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J. Clin. Invest. 75, 384-390 (1985).
4. Windler, E. & Havel, R. J. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J. Lipid Res. 26, 556-565 (1985).
5. Pollin, T. I. Et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 322, 1702-1705 (2008).
6. Tachmazidou, I. Et al. A rare functional cardioprotective APOC3 variant has risen in frequency in distinct population isolates. Nat. Commun 4, 2872 (2013).
7. Crosby, J. Et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N. Engl. J. Med. 371, 22-31 (2014).
8. Jorgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G. & Tybjaerg-Hansen, A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N. Engl. J. Med. 371, 32-41 (2014).
9. Gangabadage, C. S. Et al. Structure and dynamics of human apolipoprotein CIII. J. Biol. Chem. 283, 17416-17427 (2008).
10. Nichols, W. C., Dwulet, F. E., Liepnieks, J. & Benson, M. D. Variant apolipoprotein AI as a major constituent of a human hereditary amyloid. Biochem. Biophys. Res. Commun. 156, 762-768 (1988).
11. Benson, M. D. Et al. A new human hereditary amyloidosis: The result of a stop-codon mutation in the apolipoprotein AII gene. Genomics 72, 272-277 (2001).
12. Sethi, S. Et al. Medullary amyloidosis associated with apolipoprotein A-IV deposition. Kidney Int. 81, 201-206 (2012).
13. de Messieres, M., Huang, R. K., He, Y. & Lee, J. C. Amyloid triangles, squares, and loops of apolipoprotein C-III. Biochemistry 53, 3261-3263 (2014).
14. Valleix, S. Et al. Hereditary systemic amyloidosis due to Asp76Asn variant beta 2-microglobulin. N. Engl. J. Med. 366, 2276-2283 (2012).
15. Vrana, J. A. Et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 114, 4957-4959 (2009).
16. Naiki, H., Higuchi, K., Hosokawa, M. & Takeda, T. Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T1. Anal. Biochem. 177, 244-249 (1989).
17. Liu, H. Et al. Characterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C-III variant Ala23Thr. J. Lipid Res. 41, 1760-1771 (2000).
18. Shachter, N. S. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr. Opin. Lipidol. 12, 297-304 (2001).
19. Larsson, M., Vorrsjo, E., Talmud, P., Lookene, A. & Olivecrona, G. Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets. J. Biol. Chem. 288, 33997-34008 (2013).
20. Gregorini, G. Et al. Renal apolipoprotein A-I amyloidosis: A rare and usually ignored cause of hereditary tubulointerstitial nephritis. J. Am. Soc. Nephrol. 16, 3680-3686 (2005).
21. Benson, M. D., Liepnieks, J., Uemichi, T., Wheeler, G. & Correa, R. Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain. Nat. Genet. 3, 252-255 (1993).
22. Gillmore, J. D. & Hawkins, P. N. Pathophysiology and treatment of systemic amyloidosis. Nat. Rev. Nephrol 9, 574-586 (2013).
23. Pepys, M. B. Et al. Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature 362, 553-557 (1993).
24. Maury, C. P. Homozygous familial amyloidosis, Finnish type: demonstration of glomerular gelsolin-derived amyloid and non-amyloid tubular gelsolin. Clin. Nephrol. 40, 53-56 (1993).
25. Marchesi, M. Et al. The intracellular quality control system down-regulates the secretion of amyloidogenic apolipoprotein A-I variants: A possible impact on the natural history of the disease. Biochim. Biophys. Acta 1812, 87-93 (2011).
26. Strauss, J. G. Et al. Adenovirus-mediated rescue of lipoprotein lipase-deficient mice. Lipolysis of triglyceride-rich lipoproteins is essential for high density lipoprotein maturation in mice. J. Biol. Chem. 276, 36083-36090 (2001).
27. Jiang, X. C. Et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J. Clin. Invest. 103, 907-914 (1999).
28. von Eckardstein, A. Et al. Apolipoprotein C-III(Lys58-Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia. J. Clin. Invest. 87, 1724-1731 (1991).
29. Epstein, M. & Vaziri, N. D. Statins in the management of dyslipidemia associated with chronic kidney disease. Nat. Rev. Nephrol 8, 214-223 (2012).
30. Holzer, M. Et al. Uremia alters HDL composition and function. J. Am. Soc. Nephrol. 22, 1631-1641 (2011).
31. Mange, A. Et al. HDL proteome in hemodialysis patients: A quantitative nanoflow liquid chromatography-tandem mass spectrometry approach. PLoS ONE 7, e34107 (2012).
32. Capell, W. H. Et al. Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 23, 307-313 (2003).
33. Miller, G. J. & Miller, N. E. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1, 16-19 (1975).
34. Kawakami, A. & Yoshida, M. Apolipoprotein CIII links dyslipidemia with atherosclerosis. J. Atheroscler. Thromb. 16, 6-11 (2009).
35. Haubenwallner, S. Et al. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: A potential physiologic basis for their mode of action. J. Lipid Res. 36, 2541-2551 (1995).
36. Staels, B. Et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J. Clin. Invest. 95, 705-712 (1995).
37. Coelho, T. Et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369, 819-829 (2013).
38. Boisfer, E. Et al. Overexpression of human apolipoprotein A-II in mice induces hypertriglyceridemia due to defective very low density lipoprotein hydrolysis. J. Biol. Chem. 274, 11564-11572 (1999).
39. Chapman, M. J., Goldstein, S., Lagrange, D. & Laplaud, P. M. A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J. Lipid Res. 22, 339-358 (1981).
40. Guerin, M., Bruckert, E., Dolphin, P. J., Turpin, G. & Chapman, M. J. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 16, 763-772 (1996).
41. Guerin, M. Et al. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis 163, 287-296 (2002).
42. Kontush, A., Chantepie, S. & Chapman, M. J. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23, 1881-1888 (2003).
43. Camont, L. Et al. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler. Thromb. Vasc. Biol. 33, 2715-2723 (2013).
44. Quehenberger, O. & Dennis, E. A. The human plasma lipidome. N. Engl. J. Med. 365, 1812-1823 (2011).
45. Larrede, S. Et al. Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent. Arterioscler. Thromb. Vasc. Biol. 29, 1930-1936 (2009).
46. Fournier, N. Et al. Analysis of the relationship between triglyceridemia and HDL-phospholipid concentrations: consequences on the efflux capacity of serum in the Fu5AH system. Atherosclerosis 157, 315-323 (2001).
47. Kontush, A., de Faria, E. C., Chantepie, S. & Chapman, M. J. A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity. Atherosclerosis 182, 277-285 (2005).
48. Nobecourt, E. Et al. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia 48, 529-538 (2005).
49. Kontush, A. & Chapman, M. J. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr. Opin. Lipidol. 21, 312-318 (2010).
50. Zerrad-Saadi, A. Et al. HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 29, 2169-2175 (2009).
51. Nicolardi, S., van der Burgt, Y. E., Wuhrer, M. & Deelder, A. M. Mapping O-glycosylation of apolipoprotein C-III in MALDI-FT-ICR protein profiles. Proteomics 13, 992-1001 (2013).
52. Hawkins, P. N., Lavender, J. P. & Pepys, M. B. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N. Engl. J. Med. 323, 508-513 (1990).
53. Garnier, J., Gibrat, J. F. & Robson, B. GOR method for predicting protein secondary structure from amino acid sequence. Methods Enzymol. 266, 540-553 (1996).
54. Tartaglia, G. G. Et al. Prediction of aggregation-prone regions in structured proteins. J. Mol. Biol. 380, 425-436 (2008).
55. De Pauw, M., Vanloo, B., Weisgraber, K. & Rosseneu, M. Comparison of lipid-binding and lecithin:cholesterol acyltransferase activation of the amino-and carboxyl-terminal domains of human apolipoprotein E3. Biochemistry 34, 10953-10966 (1995).
56. Bengtsson-Olivecrona, G. & Olivecrona, T. In Lipoprotein Analysis-A Practical Approach (Oxford Univ., 1992).